INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)

Inclusion Criteria: * Newly-diagnosed brain cancer with histopathological diagnosis of GBM; * Karnofsky Performance Status (KPS) rating of \>/=70 at baseline; * Receive dexamethasone equivalent dose \</=2 mg per day, stable or decreased for \>/= three days prior to Day 0; * Recovery from the effects of prior GBM surgery as defined by the Investigator; * Electrocardiogram (ECG) with no clinically significant findings as assessed by the Investigator; * Adequate organ function as demonstrated by hematological, renal, hepatic laboratory assessments; * Agree that during the trial, men will not father a child, and women cannot be or become pregnant. Participants must be of non-child bearing potential or agree to use one highly effective or combined contraceptive methods that result in a failure rate of \<1% per year during the treatment period and at least through week 12 after last dose; * Ability to tolerate magnetic resonance imaging (MRI). Exclusion Criteria: * Presence of greater than 1 cm x 1 cm residual tumor enhancement on postoperative MRI; * Multifocal disease or leptomeningeal disease (LM) disease on post-operative MRI; * Not scheduled to start radiation within 42 days of surgical resection of tumor; * Dexamethasone equivalent dose \>2 mg per day; * Prior treatment with an agent that blocks the PD-1/PD-Ligand 1 pathway; * Receipt of previous approved or investigative immune modulatory agent within 28 days of receiving the first dose of treatment; * Prior treatment wit…